[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EP1012238A4 - Peptides and peptide-loaded antigen presenting cells for the activation of ctl - Google Patents

Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Info

Publication number
EP1012238A4
EP1012238A4 EP98906086A EP98906086A EP1012238A4 EP 1012238 A4 EP1012238 A4 EP 1012238A4 EP 98906086 A EP98906086 A EP 98906086A EP 98906086 A EP98906086 A EP 98906086A EP 1012238 A4 EP1012238 A4 EP 1012238A4
Authority
EP
European Patent Office
Prior art keywords
ctl
peptides
peptide
activation
presenting cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98906086A
Other languages
German (de)
French (fr)
Other versions
EP1012238A1 (en
Inventor
Van Tsai
Scott Southwood
John Sidney
Alessandro Sette
Esteban Celis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epimmune Inc filed Critical Epimmune Inc
Publication of EP1012238A1 publication Critical patent/EP1012238A1/en
Publication of EP1012238A4 publication Critical patent/EP1012238A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4615—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
    • A61K39/4622—Antigen presenting cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464484—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/464486—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP98906086A 1997-01-31 1998-01-30 Peptides and peptide-loaded antigen presenting cells for the activation of ctl Withdrawn EP1012238A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3669697P 1997-01-31 1997-01-31
US36696P 1997-01-31
PCT/US1998/001959 WO1998033888A1 (en) 1997-01-31 1998-01-30 Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Publications (2)

Publication Number Publication Date
EP1012238A1 EP1012238A1 (en) 2000-06-28
EP1012238A4 true EP1012238A4 (en) 2003-03-05

Family

ID=21890106

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98906086A Withdrawn EP1012238A4 (en) 1997-01-31 1998-01-30 Peptides and peptide-loaded antigen presenting cells for the activation of ctl

Country Status (5)

Country Link
EP (1) EP1012238A4 (en)
JP (1) JP2001509677A (en)
AU (1) AU6140998A (en)
CA (1) CA2278189A1 (en)
WO (1) WO1998033888A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252829B1 (en) 1998-06-17 2007-08-07 Idm Pharma, Inc. HLA binding peptides and their uses
IT1309584B1 (en) * 1999-02-26 2002-01-24 San Raffaele Centro Fond IMMUNOGENIC PEPTIDES DERIVED FROM MAGE-3 PRESENTED BY MHC OF CLASS II AND THEIR USE.
EP1917970B1 (en) * 1999-06-29 2011-06-15 Epimmune Inc. Hla binding peptides and their uses
JP4776131B2 (en) 1999-11-18 2011-09-21 エピミューン インコーポレイテッド Heteroclitic analogs and related methods
WO2001042270A1 (en) * 1999-12-10 2001-06-14 Epimmune Inc. Inducing cellular immune responses to carcinoembryonic antigen using peptide and nucleic acid compositions
US6602510B1 (en) 2000-04-05 2003-08-05 Epimmune Inc. HLA class I A2 tumor associated antigen peptides and vaccine compositions
WO2001041741A1 (en) * 1999-12-13 2001-06-14 Epimmune Inc. Hla class i a2 tumor associated antigen peptides and vaccine compositions
EP1303287A4 (en) * 2000-06-16 2006-02-08 Argonex Pharmaceuticals Mhc peptides over-expressed on prostate cancer cells and methods of use
EP1312670A4 (en) * 2000-08-16 2005-11-30 Takara Bio Inc Method of extensive culture of antigen-specific cytotoxic t cells
EP1619207A3 (en) * 2000-09-01 2006-02-08 Epimmune Inc. HLA-A2.1 binding peptides derived from HCV and their uses
WO2002072627A2 (en) * 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
AU2002305138A1 (en) 2001-04-09 2002-10-21 Mayo Foundation For Medical Education And Research Methods and materials for cancer treatment
EP2070542A3 (en) 2001-08-15 2010-01-06 Takara Bio Inc. Method of extended culture of antigen-specific cyotoxic T lymphocytes
TW201043699A (en) 2002-03-25 2010-12-16 Takara Bio Inc Process for producing cytotoxic lymphocyte
EP1620456B1 (en) 2003-04-18 2014-02-26 Biotech Synergy, Inc. Hla-a2 tumor associated antigen peptides and compositions
JPWO2005007694A1 (en) * 2003-07-16 2007-09-20 株式会社グリーンペプタイド HER2 / neu peptide and its therapeutic use
US8927273B2 (en) 2003-08-22 2015-01-06 Takara Bio Inc. Process for producing cytotoxic lymphocytes
EP1715343B1 (en) * 2005-04-20 2009-12-09 F. Hoffmann-La Roche Ag Method for the identification of epitopes related to immunogenicity in biopharmaceuticals
JP4929174B2 (en) 2005-08-17 2012-05-09 タカラバイオ株式会社 Method for producing lymphocytes
WO2010086294A2 (en) 2009-01-28 2010-08-05 Epimmune Inc. Pan-dr binding polypeptides and uses thereof
SG10201604236RA (en) 2011-05-26 2016-07-28 Geneius Biotechnology Investments Llc Modulated Immunodominance Therapy
GB201121308D0 (en) 2011-12-12 2012-01-25 Cell Medica Ltd Process
WO2013088114A1 (en) 2011-12-12 2013-06-20 Cell Medica Limited Process of expanding t cells
WO2013119947A1 (en) 2012-02-09 2013-08-15 Baylor College Of Medicine Pepmixes to generate multiviral ctls with broad specificity
JP6999941B2 (en) 2015-09-18 2022-02-10 ベイラー カレッジ オブ メディスン Identification of immunogenic antigens from pathogens and their correlation with clinical efficacy
CN105175527B (en) * 2015-10-09 2021-06-04 深圳市康尔诺生物技术有限公司 Breast cancer specific heat shock protein complex and application thereof
WO2017117418A1 (en) * 2015-12-30 2017-07-06 Anthrogenesis Corporation T lymphocyte production methods and t lymphocytes produced thereby
US20210380644A1 (en) * 2018-10-26 2021-12-09 Saint Louis University Peptides for inducing heterosubtypic influenza t cell responses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3782100B2 (en) * 1992-08-07 2006-06-07 エピミューン，インコーポレイティド HLA-binding peptide and use thereof

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BAKKER A B H ET AL: "GENERATION OF ANTIMELANOMA CYTOTOXIC T LYMPHOCYTES FROM HEALTHY DONORS AFTER PRESENTATION OF MELANOMA-ASSOCIATED ANTIGEN-DERIVED EPITOPES BY DENDRITIC CELLS IN VITRO", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, no. 22, 15 November 1995 (1995-11-15), pages 5330 - 5334, XP002032191, ISSN: 0008-5472 *
BOON T ET AL: "TUMOR ANTIGENS RECOGNIZED BY T LYMPHOCYTES", ANNUAL REVIEW OF IMMUNOLOGY, ANNUAL REVIEWS INC, US, VOL. 12, PAGE(S) 337-365, ISSN: 0732-0582, XP000882320 *
CHEN W-F ET AL: "IL-10 A NOVEL CYTOTOXIC T CELL DIFFERENTIATION FACTOR", JOURNAL OF IMMUNOLOGY, vol. 147, no. 2, 1991, pages 528 - 534, XP002220425, ISSN: 0022-1767 *
KAWASHIMA I ET AL: "IDENTIFICATION OF GP100-DERIVED, MELANOMA-SPECIFIC CYTOTOXIC PRIMARY IN VITRO IMMUNIZATION WITH PEPTIDE-PULSED DENDRITIC CELLS. T-LYMPHOCYTE EPITOPES RESTRICTED BY HLA-A3 SUPERTYPE MOLECULES BY", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 78, no. 4, 1998, pages 518 - 524, XP000917221, ISSN: 0020-7136 *
ROMANI N ET AL: "PROLIFERATING DENDRITIC CELL PROGENITORS IN HUMAN BLOOD", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 180, no. 1, 1 July 1994 (1994-07-01), pages 83 - 93, XP000610046, ISSN: 0022-1007 *
See also references of WO9833888A1 *
TSAI V ET AL: "IDENTIFICATION OF SUBDOMINANT CTL EPITOPES OF THE GP 100 MELANOMA-ASSOCIATED TUMOR ANTIGEN BY PRIMARY IN VITRO IMMUNIZATION WITH PEPTIDE-PULSED DENDRITIC CELLS", JOURNAL OF IMMUNOLOGY, THE WILLIAMS AND WILKINS CO. BALTIMORE, US, vol. 158, no. 4, 1997, pages 1796 - 1802, XP000919288, ISSN: 0022-1767 *
YANG GUCHEN ET AL: "In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation.", JOURNAL OF IMMUNOLOGY, vol. 155, no. 8, 1995, pages 3897 - 3903, XP002220424, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO1998033888A1 (en) 1998-08-06
AU6140998A (en) 1998-08-25
CA2278189A1 (en) 1998-08-06
JP2001509677A (en) 2001-07-24
EP1012238A1 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
EP1012238A4 (en) Peptides and peptide-loaded antigen presenting cells for the activation of ctl
SG49113A1 (en) Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
HK1096974A1 (en) Antibody against human parathormone related peptides
IL128529A0 (en) Anti-inflammatory peptides and uses thereof
GB9701293D0 (en) Reflector device and display incorporating same
ZA969443B (en) Peptides which enhance transport across tissues and methods of identifying and using the same
AU7158398A (en) Use of lentiviral vectors for antigen presentation in dendritic cells
ZA95261B (en) T cell antigen receptor V region proteins and methods of preparation thereof
EP1055684A4 (en) Tumor antigen peptide derivatives
IL145850A0 (en) Adhesion modulatory peptides and methods for use
GB9705903D0 (en) VP22 Proteins and uses thereof
AU2768597A (en) Novel peptides suitable for use in antigen specific immunosuppressive therapy
AU1598500A (en) Hla-a2 and hla-dr specific peptide epitopes from the melanoma antigen trp2
AU6649698A (en) Peptide probes to coil proteins and methods for making the same
AU4236097A (en) Mhc peptides and methods of use
AU2087799A (en) Diagnostic and therapeutic methods based upon valpha24jalphaq t cells
AU2408397A (en) Ob protein receptor genes and use of the same
AU7308200A (en) Novel hev antigenic peptide and methods
AU8010698A (en) Method and device for enabling non-destructive determination of the elasticity of materials
AUPN024994A0 (en) Assay and peptides for use therein
GB9714276D0 (en) Peptides and related compounds
GB2336844B (en) Anti-hiv peptides and proteins
AU8679498A (en) Immunologically privileged cells and uses thereof
AU5915998A (en) Battery belt assembly and related methods
GB9704162D0 (en) Assay methods and means

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990812

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: EPIMMUNE INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12N 9/08 B

Ipc: 7C 12N 5/08 B

Ipc: 7C 12N 5/06 A

A4 Supplementary search report drawn up and despatched

Effective date: 20030121

18D Application deemed to be withdrawn

Effective date: 20020801